March 24, 2025

Tildrakizumab Shows Lasting Efficacy in Scalp Psoriasis

Tildrakizumab may provide durable response for scalp psoriasis, a phase 3b study found, confirming sustained efficacy and safety through 52 weeks.

Conexiant

March 24, 2025

TPT Lowers Tuberculosis Risk in Rheumatic Patients

TPT decreased the overall risk of tuberculosis disease in patients with rheumatic diseases, with a 76% risk reduction observed in certain subgroups, researchers reported.

Conexiant

March 21, 2025

FDA Approves Guselkumab for Crohn’s Disease

The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters

March 06, 2025

An Estimated 31 Million Americans Borrowed for Medical Bills in 2024

A new West Health-Gallup Survey survey reveals insights into medical debt across all income levels and demographics in the United States.

Conexiant

March 04, 2025

FDA Approves Prefilled Syringe for Cortrophin Gel

FDA approves a prefilled syringe format for Purified Cortrophin Gel, reducing administration steps for patients with inflammatory and autoimmune conditions.

Conexiant

March 03, 2025

More States Fast Track Foreign-Trained Physicians

Since 2023, nine states have waived U.S. residency requirements for some foreign-trained physicians, with more states considering similar changes.

KFF Health News

March 03, 2025

mRNA Boosters Drive Antibody Evolution in Immunosuppressed Patients

Successive mRNA vaccinations enhanced cross-variant antibody evolution in immunosuppressed patients, though responses varied by treatment type, according to a new study.

Conexiant